Adding ibrutinib to obinutuzumab in the first-line setting sustains progression-free survival (PFS) benefit in patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL), including patients with high-risk genomic features, according to the ﬁnal analysis of the iLLUMINATE* trial.
Non-O blood type appears to be a risk factor for cancer-associated venous thromboembolism (VTE), particularly in patients who have cancer types with low to intermediate thrombotic risk, according to data from the Cancer and Thrombosis Study (CATS) presented at ASH 2021.
Low platelet counts, along with low levels of interleukin (IL)-15 and granulocyte-macrophage colony-stimulating factor (GM-CSF), seem to be good prognostic indicators of metastatic disease in patients with pancreatic ductal adenocarcinoma (PDAC), a recent study has found.
The risk of pancreatic ductal adenocarcinoma (PDAC) appears to be higher among individuals with diabetes than in the general population, as well as in men than women, according to a study. Prediction models built around this finding demonstrate moderate accuracy for pinpointing men at high risk of PDAC, in whom surveillance may be required.
Supplementation with vitamin D, otherwise called sunshine vitamin, and calcium may help women with breast cancer protect against bone loss associated with aromatase inhibitors (AIs), suggests a 5-year follow-up study from Brazil.
People who consume more olive oil in their diet have a lower risk of death from any cause or specific causes including cardiovascular disease (CVD), cancer, neurodegenerative disease, or respiratory disease compared with those who hardly or never consume olive oil, according to a large US study.
Patients with de novo metastatic invasive lobular carcinoma display unique and heterogeneous clinicopathological characteristics, metastasis patterns, and responses to treatment, a recent study has found.
In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.
The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.